Positive results of adjuvant mitomycin-C in resected gastric cancer: A randomised trial on 134 patients

Grau, Juan J.; Vila, Jordi; Alcobendas, F; Pera, Cristóbal; Daniels, M.; Terés, J

doi:10.1016/0959-8049(93)90381-o

Cited by 59 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…up suggested a 15% improvement in the 5-year survival rate for the treated group (41% vs 26%, P<0.025) [13]. However, only 68 patients on this trial received mitomycin.…”

Section: Single Agentsmentioning

confidence: 73%

Adjuvant and preoperative chemotherapy for gastric cancer

Yao

Ajani

2002

Curr Oncol Rep

View full text Add to dashboard Cite

Gastric cancer is the second most frequently diagnosed malignancy worldwide, and the risk of relapse remains high in the majority of patients undergoing resection. Attempts to reduce this risk and prolong survival have led to numerous adjuvant chemotherapy trials that either had no benefit for patients or occasionally had controversial results. The recently reported Intergroup 0116 trial shows conclusive evidence of survival benefit for patients treated with postoperative chemoradiotherapy. In this Intergroup trial, which involves over 600 patients, a regimen of postoperative chemotherapy plus chemoradiotherapy was shown to prolong overall and disease-free survival in gastric cancer patients with stage IB through IV disease following a curative (R0) resection. This approach should be considered the standard of care in patients with gastric cancer who have undergone curative resection. Preoperative chemotherapy shows promise in downstaging tumors and increasing the rate of curative resection, but randomized trials are needed to assess survival benefits. Efforts to combine existing treatment modalities and new agents with novel mechanisms of action hold promise for the future.

show abstract

“…up suggested a 15% improvement in the 5-year survival rate for the treated group (41% vs 26%, P<0.025) [13]. However, only 68 patients on this trial received mitomycin.…”

Section: Single Agentsmentioning

confidence: 73%

Adjuvant and preoperative chemotherapy for gastric cancer

Yao

Ajani

2002

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…As the doubling time of tumor is often shorter in a small pop ulation focus than in a larger one, tumor foci remaining after surgery are expected to be more sensitive to anticancer drugs [27,28]. Recently, Estape et al [29] and Grau et al [30] reported that adjuvant MMC after curative resection is an effective treatment and that its effects remain evident even after 10 years of follow-up. We reported the effectiveness of postoperative chemotherapy, particularly for a limited subset of gastric cancers treated with selected chemotherapeutic regimens [5, 31,32].…”

Section: Discussionmentioning

confidence: 99%

Postoperative Chemotherapy for Gastric Cancer in the Elderly

Maehara¹,

Yamamoto

Endo

et al. 1994

Chemotherapy

View full text Add to dashboard Cite

Prolongation of the life span and improvement in technology make it more likely that the elderly will be surgically treated and chemotherapy will be prescribed, postoperatively. The relationship between postoperative chemotherapy and survival time after resection for gastric cancer in the elderly was examined in a retrospective review of data on 268 patients over the afe of 70 years; all had been treated in the Department of Surgery II, between 1965 and 1987. Of these 268 patients, 161 were prescribed anticancer drugs, postoperatively. Postoperative chemotherapy was more often prescribed for those in the advanced stages of a malignancy. The survival time of those patients was shorter than for those who did not receive these drugs (p < 0.05). In a subgroup of our patients stratified to adjust for stage of the disease, there were no significant differences between the survival rates in cases of stages I, II or IV of the cancer. The survival time of patients with stage III and given chemotherapy improved compared to those not given chemotherapy (p < 0.01). Advanced chronological age is not sufficient justification to limit or withhold treatment with anticancer drugs. We propose that postoperative chemotherapy be prescribed for patients with gastric cancer, regardless of age.

show abstract

“…No attempt was made to identify ongoing trials with unpublished results. For studies published more than once during follow-up, only the last: nal version, or the one presenting the most detailed results, have been included (24)(25)(26)(27)(28)(29)(30)(31). Two studies included in the earlier meta-analysis (23), one using immuno-therapy and the other only published in Japanese, were excluded in this analysis.…”

Section: Comments On the Included Studiesmentioning

confidence: 99%

A Systematic Overview of Chemotherapy Effects in Gastric Cancer

Janunger

2001

Acta Oncologica

View full text Add to dashboard Cite

Positive results of adjuvant mitomycin-C in resected gastric cancer: A randomised trial on 134 patients

Cited by 59 publications

References 17 publications

Adjuvant and preoperative chemotherapy for gastric cancer

Adjuvant and preoperative chemotherapy for gastric cancer

Postoperative Chemotherapy for Gastric Cancer in the Elderly

A Systematic Overview of Chemotherapy Effects in Gastric Cancer

Contact Info

Product

Resources

About